scholarly article | Q13442814 |
P356 | DOI | 10.1007/S40620-014-0045-4 |
P698 | PubMed publication ID | 24515315 |
P50 | author | Ismail Kocyigit | Q79364273 |
Eray Eroglu | Q83287759 | ||
Fahir Ozturk | Q86628654 | ||
Özcan Örsçelik | Q89439467 | ||
Hakan İmamoğlu | Q91558509 | ||
Unal Aydin | Q94470735 | ||
Ozkan Gungor | Q97594903 | ||
Bülent Tokgöz | Q116884257 | ||
Murat Hayri Sipahioglu | Q117241427 | ||
Oktay Oymak | Q117241428 | ||
Cigdem Karakukcu | Q61106980 | ||
P2860 | cites work | Autosomal dominant polycystic kidney disease | Q72805647 |
Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents | Q72888041 | ||
Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function | Q80050909 | ||
Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease | Q80316793 | ||
Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients | Q84379418 | ||
Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease | Q87149663 | ||
Autosomal dominant polycystic kidney disease: the last 3 years | Q24656249 | ||
Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease | Q24657714 | ||
Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program | Q28285436 | ||
C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies | Q33312953 | ||
Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? | Q33345061 | ||
Hypertension in autosomal dominant polycystic kidney disease | Q33754691 | ||
Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease | Q33997369 | ||
PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation | Q34106947 | ||
Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study | Q34150807 | ||
Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. | Q34324823 | ||
Inflammation, Oxidative Stress, and Insulin Resistance in Polycystic Kidney Disease | Q34497281 | ||
Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes | Q34751855 | ||
The clinical implications of endothelial dysfunction | Q35548796 | ||
The long pentraxin PTX3 in vascular pathology | Q36615475 | ||
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease | Q36736700 | ||
Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? | Q37832075 | ||
Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality | Q44571381 | ||
Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease | Q44581660 | ||
Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells | Q44985116 | ||
Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. | Q48770462 | ||
The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality. | Q53496784 | ||
Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. | Q54043582 | ||
P433 | issue | 2 | |
P921 | main subject | inflammation | Q101991 |
endothelium | Q111140 | ||
autosomal dominant polycystic kidney | Q2732398 | ||
autosomal dominant polycystic kidney disease | Q15443105 | ||
P304 | page(s) | 181-186 | |
P577 | publication date | 2014-02-11 | |
P1433 | published in | Journal of Nephrology | Q15765408 |
P1476 | title | Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease | |
P478 | volume | 27 |
Q36284659 | Biomarkers and surrogate endpoints in kidney disease |
Q40865321 | Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function |
Q38683930 | Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima-media thickness. |
Q64104744 | Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies |
Q49909712 | Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment |
Q90324149 | The association of endothelin-1 levels with renal survival in polycystic kidney disease patients |
Q47626900 | Update on the role of Pentraxin 3 in atherosclerosis and cardiovascular diseases |
Search more.